TY - JOUR
T1 - Treat cancers by targeting survivin
T2 - Just a dream or future reality?
AU - Coumar, Mohane Selvaraj
AU - Tsai, Fang Ying
AU - Kanwar, Jagat Rakesh
AU - Sarvagalla, Sailu
AU - Cheung, Chun Hei Antonio
N1 - Funding Information:
This work is kindly supported by the following grants: NSC100-2314-B-006 -075 and NSC101-2320-B-006-041 ( National Science council, Taiwan, ROC ); NHRI-EX102-10237SC (National Health Research Institutes, Taiwan, ROC); “Aim for the Top University Project” ( National Cheng Kung University, Taiwan, ROC ) and NCKUH-10007012 ( National Cheng Kung University Hospital, Taiwan, ROC ).
PY - 2013/11
Y1 - 2013/11
N2 - Since the discovery of survivin (BIRC5) as a cancer-related molecule by Grazia Ambrosini and Dario C. Altieri at 1997, our knowledge related to the function of this molecule has been extended from simple apoptosis inhibition to complicated, interlinked processes that involve interference of mitosis, apoptosis, autophagy, and even DNA repair recently. However, despite the growing amount of knowledge related to survivin in the last ten years, the development of survivin inhibitors or survivin-related molecular therapies is surprisingly and relatively slow as compared to other therapeutic inhibitors for cancer treatment. Here, the molecular functions of survivin and the progress of development of survivin-targeting therapies are discussed in detail. Functional differences between different survivin-specific inhibitors are discussed from both structural and biochemical point of views. This review also reveals different challenges that scientists are currently facing in the development of survivin inhibitors for clinical application. Finally, future directions for the development of survivin-targeted therapies are discussed in this review.
AB - Since the discovery of survivin (BIRC5) as a cancer-related molecule by Grazia Ambrosini and Dario C. Altieri at 1997, our knowledge related to the function of this molecule has been extended from simple apoptosis inhibition to complicated, interlinked processes that involve interference of mitosis, apoptosis, autophagy, and even DNA repair recently. However, despite the growing amount of knowledge related to survivin in the last ten years, the development of survivin inhibitors or survivin-related molecular therapies is surprisingly and relatively slow as compared to other therapeutic inhibitors for cancer treatment. Here, the molecular functions of survivin and the progress of development of survivin-targeting therapies are discussed in detail. Functional differences between different survivin-specific inhibitors are discussed from both structural and biochemical point of views. This review also reveals different challenges that scientists are currently facing in the development of survivin inhibitors for clinical application. Finally, future directions for the development of survivin-targeted therapies are discussed in this review.
UR - http://www.scopus.com/inward/record.url?scp=84881547700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881547700&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2013.02.002
DO - 10.1016/j.ctrv.2013.02.002
M3 - Review article
C2 - 23453862
AN - SCOPUS:84881547700
SN - 0305-7372
VL - 39
SP - 802
EP - 811
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
IS - 7
ER -
